Therapy with monoclonal antibodies belongs to a class of drugs that mimics the natural antibodies produced by the body to fight infection
One of the treatment routes being tested for Covid-19 is monoclonal antibodies; however, its results are not being particularly encouraging. The latest bad news was just presented by the Anglo-Swedish pharmaceutical AstraZeneca, which reported today that its treatment with monoclonal antibodies, AZD7442, has not met the main objective to prevent symptomatic Covid-19 in people exposed to the coronavirus.
Participants in this clinical trial they were unvaccinated adults over 18 years of age with confirmed exposure to coronavirus in the last eight days.
AZD7442 reduced the risk of developing symptomatic Covid-19 by one 33% in comparison with a placebo, which is not considered statistically significant.
“Although this trial failed to achieve the primary endpoint, the protection seen in PCR-negative participants after AZD7442 treatment is relevant,” he stated. Mene Pangalos, Executive Vice President of AstraZeneca, in a statement.
AstraZeneca is also studying the treatment in a trial of pre-exposed patients and to prevent more serious diseases.
Monoclonal antibody therapy is in a class of drugs that mimics the natural antibodies the body makes to fight infection.
Regeneron Pharmaceuticals Inc y Eli Lilly & Co have developed monoclonal antibody therapies to treat patients infected with the virus. Both have been licensed for use in the US, while the European Medicines Agency (EMA) has already approved Regeneron’s therapy and is reviewing similar drugs from Eli Lilly, Celltrion, and one developed by GlaxoSmithKline and Vir Biotechnology Inc .